Tag Archives: FasterCures
Research!America To Honor Leaders in Medical and Health Research Advocacy
Robin Roberts, Michael Milken, Dr. Kenneth Olden, David Van Andel, Dr. George Vande Woude and the Society for Neuroscience to Receive 2015 Research!America Advocacy Awards
ALEXANDRIA, Va.—September 29, 2014—Research!America’s 19th annual Advocacy Awards will honor distinguished research advocates who are trailblazers in advancing medical progress to improve the health and economic security of our nation. The event will take place on Wednesday, March 11, 2015, at the Andrew W. Mellon Auditorium in Washington, DC.
The 2015 Advocacy Award winners are ABC’s “Good Morning America” anchor Robin Roberts; Michael Milken, founder of the Milken Institute and FasterCures; Dr. Kenneth Olden, Director, National Center for Environmental Assessment, U.S. EPA; David Van Andel, Chairman and CEO, and Dr. George Vande Woude, Founding Scientific Director, Van Andel Research Institute; and the Society for Neuroscience (SfN).
“These exceptional leaders have advanced scientific discovery and innovation through their determination to improve the health of individuals worldwide,” said Mary Woolley, president and CEO of Research!America. “Their work has paved the way for others who are committed to ensuring that we save lives and sustain our nation’s global competitiveness with robust support for research.” Continue reading →
Dear Research Advocate:
The loss of American Icon Robin Williams has riveted national attention on suicide, one of the 10 most common causes of death in the United States. Today, we are releasing our updated fact sheet on suicide that you can use when meeting with lawmakers and educating others about the impact research can have. Efforts to prevent suicide rightly draw on research findings. But progress has been painfully slow, stymied by serious gaps – partly due to severely limited funding – in the basic research base that precedes private sector development, and stymied by the equivalent of handcuffs placed on social science research.
The notion promulgated by some in the Congress that social sciences research doesn’t add enough value to merit federal funding is not just unfounded, it’s holding us back. Social sciences research saves lives. Case in point: behavioral research guided the development of a suicide intervention that was pilot tested in schools in Georgia and Connecticut and resulted in a 40% reduction in attempted suicides. It has since been implemented in schools across the country. This is just one example of social sciences research at work.
Research moves faster when patient advocates engage. This is the history of the nation’s commitment to defeating polio, to ramping up HIV/AIDS research, to prioritizing breast cancer research and women’s health research overall. Writing in the New Yorker last month, Seth Mnookin described the impact that “dedicated … well-informed families” can have in pushing progress. In his responsive letter to the editor, Peter L. Saltonstall, CEO of the National Organization for Rare Disorders, focused on the use of social media by patient groups to establish global registries, taking full advantage of abilities we didn’t have just a few years ago, and in so doing, saving lives. But there is another message here. The research community must work more closely with patient advocates in order to drive medical innovation. As one of the researchers in the Mnookin article said, “Gone are the days when we could just say, ‘We’re a cloistered community of researchers, and we alone know how to do this.’” Continue reading →
Dear Research Advocate:
The omnibus appropriations bill about to become law demonstrates that bipartisanship and pseudo-regular order is achievable. We won’t know for sure if we have true “regular order” until Congress proceeds through the FY15 appropriations process in a timely manner — something that hasn’t happened for many years. The importance of regular order is that the public’s interests are heard from in hearings, and every Member of Congress participates in priority-setting instead of only having the opportunity to cast a single up-or-down vote. Regular order is worth working toward, since at least one priority we all care about did not fare well in the omnibus.
The omnibus has failed to fund NIH at a level that fully reverses the impact of sequestration on the agency’s baseline funding level, much less establishes a growth trend that can fully unleash the potential inherent in the sequencing of the human genome and other research breakthroughs. As Drs. Paul Stoffels and Alan Leshner make crystal clear in an op-ed in Politico Magazine, we can’t settle for “better than sequestration.” If our nation wants to thrive, we need to grow our investment in science. Between 2010 and 2013, U.S. federal investments in science fell to less than 1% (.82%) of the economy. That’s the lowest it’s been in 50 years! As you know, this comes at a time when foreign nations are rapidly ramping up their R&D programs and taking a page from our playbook. Remember that global competitiveness in medical research is a pivotal determinant of our global economic competitiveness overall. We aren’t just talking about the future of our scientific enterprise, we are talking about the future of our economy. Are we truly willing to cede leadership in global R&D? (See also our statement cited in The Hill and other media outlets, as well as my interview today with UDC.) Continue reading →
A Weekly Advocacy Message from Mary Woolley: Help set our nation’s sights high on the Fourth of July
Dear Research Advocate:
Setting our nation’s sights high, rather than watching Rome burn; that’s the advice embedded in a recent op-ed authored by John R. Seffrin, PhD (CEO of the American Cancer Society and Research!America Board Member) and Michael Caligiuri, MD (CEO of the Ohio State University Comprehensive Cancer Center – James Cancer Center Hospital and Solove Research Institute). The authors advocate establishing a national plan, one that puts political differences aside and focuses on combating deadly and tremendously costly disease.
There is a compelling argument to be made that if our nation wants to sustain a balanced budget, it must deploy a disease moonshot. If our nation wants to protect the health and safety of Americans, lead medical progress instead of abandoning it, and fix the debt, health and medical research must be treated as a top national priority. Advocacy is a path that can take us there, if enough of us travel it and we raise our voices loud enough. Join us next week as we continue our national “#curesnotcuts” social media campaign during the 4th of July Congressional Recess. Check here for more information including sample messages. An article in the Portland Tribune and the ongoing regional radio interviews that I’m conducting over the recess are examples of recent media that effectively frame what’s at stake.The goal is to keep research in the news and in the hearts and minds of our nation’s decision-makers. Continue reading →
This month “Genome: Unlocking Life’s Code,” first state-of-the-art exhibition about genome science, opened at the Museum of Natural History in partnership with the National Human Genome Research Institute (NHGRI). The exhibit boasts cutting-edge interactives, 3D models, custom animations and engaging videos of real-life stories. According to Dr. Eric D. Green, director of the National Human Genome Research Institute (NHGRI), one of the 27 institutes and centers that make up the National Institutes of Health (NIH), “This exhibition reflects a remarkably productive collaboration between components of two scientific icons of the U.S. government – the Smithsonian Institution and the National Institutes of Health.”
The Human Genome Project (HGP), which is celebrating its 10th anniversary, has helped researchers gain a better understanding of genes, opening pathways to new innovations for health and technology. Before the project, researchers knew the genetic basis of about 60 rare genetic diseases; when it ended the number had jumped to 2,200. Today, with research energized by the HGP, we know the genomic basis of nearly 5,000 rare disorders, according to the exhibits website. Continue reading →
We’ve heard plenty in the media about sequestration’s impact to federal agencies including furloughs and short-lived—delays at airports, but how is the biomedical research community dealing with the across-the-board cuts? The word “furlough” is something you would never hear in a research lab; time-sensitive research experiments cannot simply be put on hold. So how will the shortfall in budgets be met? Many researchers and universities are making tough decisions that could delay promising studies and result in layoffs.
Below are resources with more details about sequestration’s impact to science and the economy. Continue reading →